Clinical trials: Hemophagocytic Lymphohistiocytoses
Hemophagocytic Lymphohistiocytoses, Cytokine Storm
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children.
- Trial name
- NCT05491304
- Testing
- Dexamethasone, Etoposide, Ruxolitinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
PD-1 Antibody, Mixed Chimerism
PD-1 Antibody Improve Mixed Chimerism
PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape.
- Trial name
- HLH (NCT04944511)
- Testing
- Toripalimab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Leukemia
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH.
- Trial name
- NCT02385110
- Testing
- Alemtuzumab, Etoposide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Hemophagocytic Lymphohistiocytosis
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
This study aimed to investigate the efficacy and safety of L-DEP (L-Asparaginasum, liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for relapse/refractory EBV associated…
- Trial name
- NCT05315336
- Testing
- L-DEP and PD-1 antibody
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
COVID-19
Etoposide in Patients With COVID-19 Infection
This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection.
- Trial name
- NCT04356690
- Testing
- Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Boston Medical Center
Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or…
- Trial name
- NCT03827343
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Hemophagocytic Syndrome
Children and Adult Hemophagocytic Syndrome (HLHa)
Different study of HLHa patients : Diagnosis criteria, because criteria are based on pediatric genetic studies. Physiopathological studies: genetic studies have demonstrated the role of CD8+ cells, in particular because they have…
- Trial name
- HLH-genes (NCT02113917)
- Testing
- Identification of biological markers
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophagocytic Lymphohistiocytosis
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Despite good progress during the last decade, hemophagocytic lymphohistiocytosis (HLH) remains difficult to treat. Two different treatment regimens have been used successfully.
- Trial name
- NCT01104025
- Testing
- ATG, rabbit, Etoposide, Methotrexate
- Where
- 15 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
NHL With Hemophagocytic Lymphohistiocytosis
Trial of DA-EPOCH Regimen for NHL With HLH
The major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic lymphohistiocytosis
- Trial name
- NCT01818908
- Testing
- DA-EPOCH
- Where
- 4 sites in China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Hemophagocytic Lymphohistiocytoses
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated…
- Trial name
- NCT05898477
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Alabama at Birmingham
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
- Trial name
- NCT04979884
- Testing
- cyclosporine
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Hemophagocytic Lymphohistiocytoses, Lymphoma
Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
Lymphoma-associated hemophagocytic lympohistiocytosis is a refractory immune disorder with high mortality. Early identification and diagnosis of lymphoma-associated HLH has become the key to improve the prognosis of…
- Trial name
- NCT05600959
- Testing
- cytokine
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Beijing Friendship Hospital
EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) or EBV infection
- Trial name
- NCT06135922
- Testing
- EBV-TCR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
Immune Deficiency Disorders, Severe Combined Immunodeficiency
Immune Disorder HSCT Protocol
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders.
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia
- Trial name
- NCT01821781
- Testing
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Patients will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, patients will be given very strong doses of chemotherapy, which will kill all their existing stem cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia
- Trial name
- DOTTI (NCT01494103)
- Testing
- iCaspase9-transduced T cells, AP1903
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Hemophagocytic Lymphohistiocytosis
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody
International, multicenter, long-term, follow-up study that will enrol HLH participants who have received emapalumab in previous clinical trials, in the context of the clinical development program for emapalumab or under…
- Trial name
- NCT02069899
- Testing
- Emapalumab
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 58 people
- Sponsor
- Swedish Orphan Biovitrum
Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
A study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers…
- Trial name
- NCT07208058
- Testing
- Plonmarlimab
- Where
- 18 sites in China
- Volunteers
- 30 people
- Sponsor
- TJ Biopharma Co., Ltd.
Lymphoma, Hemophagocytic Lymphohistiocytoses
Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas
The goal of this study is to explore the associations between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas.
- Trial name
- LA-HLH (NCT06585124)
- Testing
- Flow Cytometry
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Primary Hemophagocytic Lymphohistiocytosis
Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis
The goal of this retrospective study is to assess efficacy and safety of emapalumab prescribed for the treatment in children with refractory from of pHLH.
- Trial name
- CGM EMA (NCT06587191)
- Where
- Russia
- Volunteers
- 7 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Lymphoma, Haemophagocytic Lymphohistiocytosis
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Haemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening blood disease which causes severe inflammation with symptoms similar to severe sepsis. It is hard to diagnose.
- Trial name
- NCT05702502
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Nottingham University Hospitals NHS Trust